Rapid Micro Biosystems, a Bedford, MA-based provider of microbial detection for quality control testing within the pharmaceutical and personal care products market segments, raised $32.6m in Series B financing.
The round was led by Longitude Capital and TPG Biotech with participation from existing investors Kleiner Perkins Caufield & Byers, TVM Capital and Quaker Partners. In conjunction with the funding, Dr. Mark Braganza, Principal at TPG Biotech and Dr. David Hirsch, Managing Director at Longitude Capital will be joining Rapid Micro Biosystems’ board of directors.
The company intends to use the funds to expand the commercial and manufacturing operations in support of the Growth Direct™ System and the companion applications including environmental monitoring, sterility and bioburden testing.
Led by Steve Delity, President and CEO, Rapid Micro Biosystems provides the Growth Direct™ System, a technology that automates and accelerates detection and enumeration in the areas of sterility testing, environmental monitoring, and bioburden testing, eliminating manual steps and analysis.